close

Enter

Log in using OpenID

Hormone Replacement Therapy Market

embed
New mergers and acquisitions is one of the major factor driving the growth of the hormone replacement therapy market.
Hormone Replacement Therapy Market Trends, and Forecast to 2026
New mergers and acquisitions is one of the major factor driving the growth of the hormone
replacement therapy market. For instance, in 2014, Pfizer Inc., a U.S.-based pharmaceutical
company, merged with OPKO Health Inc., a U.S.-based company, to develop a long acting
growth hormone (hGH-CTP) and innovative treatments for growth hormone deficient patients.
hGH-CTP is more convenient, as the patients need to take just one injection in a week rather
than daily doses. hGH-CTP has an orphan drug designation in the U.S. and Europe for adults
and children with growth hormone deficiency.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/2079
Robust pipeline is also expected to support growth of the hormone replacement therapy market
size. For instance, Somapacitan sponsored by Novo Nordisk A/S, a Denmark-based company,
completed phase 3 clinical trials in 2017. This drug is used for the treatment of growth
hormone deficiency in adults.
The global hormone replacement therapy market size was valued at US$ 10.58 billion in 2017
and is expected to witness a CAGR of 5.2% over the forecast period (2018 – 2026).
Market Dynamics
Increasing number of people suffering from hypogonadism and rising adoption of testosterone
products in various economies is expected to propel overall growth of the market. According to
the data published in the European Association of Urology Journal: 2017, testosterone
prescription trends in the U.S. exhibited an increase between 1.8- and 4-fold over the last two
decades (1997 - 2017). Moreover, from 2000 to 2011, there was a 4.3-fold increase in
testosterone testing when compared to a 3.7-fold increase in prescriptions.
Rising number of generic versions of hormone replacement therapies by various manufacturers
will drive growth of the market in terms of volume and value. For instance, Teva
Pharmaceutical Industries Ltd. launched the generic Axiron1 (testosterone) topical solution CIII,
30 mg/1.5 mL, in the U.S. on August 18, 2017 to treat adult males who have low or no
testosterone due to certain medical conditions. This solution was supplied in a metered dose
pump with an underarm applicator.
Report includes chapters which deeply display the following deliverable about industry :
• Hormone Replacement Therapy Market Research Objective and Assumption
• Hormone Replacement Therapy Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Hormone Replacement Therapy Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Hormone Replacement Therapy Market, By Regions
• Hormone Replacement Therapy Market Competition by Manufacturers including Production,
Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Hormone Replacement Therapy Market Manufacturers Profiles/Analysis including Company
Basic Information, Manufacturing Base and Its Competitors.
• Hormone Replacement Therapy Market Manufacturing Cost Analysis including Key Raw
Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Hormone Replacement Therapy Market Forecast including Production, Consumption, Import
and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Increasing prevalence of various chronic conditions are expected to drive growth of the
hormone replacement therapy market
Increasing prevalence of hypogonadism in adult men worldwide is expected to drive growth of
the hormone replacement therapy market.
According to the European Association of Urology: 2016 report, in middle-aged men, the
incidence of hypogonadism varies from 2.1% to 12.8%. The incidence of low testosterone and
symptoms of hypogonadism in men aged 40-79 varies form 2.1% to 5.7%, in Europe.
Inquire Here Before Purchase of Research Report @
https://www.coherentmarketinsights.com/insight/talk-to-analyst/2079
Ease in access and government support for research and development activities is expected to
aid in growth of the hormone replacement therapy market. Financial help by NGOs such as the
National Gaucher Society help patients receive enzyme replacement therapy that are costly.
Key players covered as a part of this study include Novartis AG, Abbott Laboratories, Mylan
NV, Merck KgaA, Bayer AG, Pfizer Inc., Novo Nordisk A/S, QuatRx Pharmaceuticals, Teva
Pharmaceutical Industries Ltd., Amgen, Inc., and Eli Lilly and Company
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Author
Alex Huge
Alex Huge395   documents Email
Document
Category
Health and Medicine
Views
24
File Size
108 KB
Tags
replacement, Hormone Replacement Therapy Market
1/--pages
Report inappropriate content